Sara Monti to Pandemics
This is a "connection" page, showing publications Sara Monti has written about Pandemics.
Connection Strength
0.059
-
Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis. Ann Rheum Dis. 2020 12; 79(12):1658-1659.
Score: 0.030
-
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al. Ann Rheum Dis. 2021 01; 80(1):e11.
Score: 0.007
-
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. Ann Rheum Dis. 2021 01; 80(1):e3.
Score: 0.007
-
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit. Ann Rheum Dis. 2020 06; 79(6):e62.
Score: 0.007
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 05; 79(5):667-668.
Score: 0.007